Kamada's Phase 2 Trial Of Alpha-1 Antitrypsin Therapy Meets Primary Endpoint

(RTTNews) - Kamada Ltd. (KMDA) Tuesday announced positive top-line results, meeting the primary endpoint of its Phase 2 clinical trial of its proprietary inhaled Alpha-1 Antitrypsin therapy for the treatment of Alpha-1 Antitrypsin Deficiency or AATD. The double-blind, placebo-controlled study evaluated the safety and efficacy of AAT by inhalation in 36 AATD patients.

AATD is an orphan disease currently treated by intravenous AAT augmentation therapy. Patients were treated with Kamada's AAT for inhalation or placebo via the eFlow device for 12 weeks during the double-blind period. Primary efficacy measures included antigenic AAT levels and Anti-Neutrophil Elastase inhibitory levels in the lung as well as additional anti-proteolitic and anti-inflammatory biomarkers.

AATD patients treated with Kamada's inhaled AAT demonstrated a significant increase in endothelial lining fluid AAT antigenic level compared to the placebo group.

Amir London, chief executive officer of Kamada said, "We strongly believe our inhaled AAT has the potential to change the treatment paradigm for AATD."